Improved detection of recurrent bladder cancer using the bard bta stat test

Sarosdy, Michael F.; Hudson, M’Liss A.; Ellis, William; Soloway, Mark S.; White, Ralph deVere; Sheinfeld, Joel; Jarowenko, Mark V.; Schellhammer, Paul F.; Schervish, Edward; Patel, Jaina; Chodak, Gerald W.; Lamm, Donald L.; Johnson, Rylee; Henderson, Maureen; Adams, George W.; Blumenstein, Brent A.; Thoelke, K.R.; Pfalzgraf, Robert; Murchison, H.A.; Brunelle, Serge

doi:10.1016/s0090-4295(97)00292-6

Cited by 178 publications

(56 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 allow us to perform a rough calculation of the number of X52.1 target molecules present on a rabbit erythrocyte, yielding an estimate of ϳ480,000 fixed C3b molecules per RE during rapid activation. 3 This number agrees reasonably well with the measurement made by Fishelson et al of 380,000 deposited C3b molecules per RE under similar conditions (35).…”

Section: Summary Of Hemolysis Results and Control Proceduressupporting

confidence: 92%

See 1 more Smart Citation

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Corey¹,

Kinders²,

Poduje³

et al. 2000

Journal of Biological Chemistry

View full text Add to dashboard Cite

We have recently reported that complement factor H, a negative regulator of complement-mediated cytotoxicity, is produced and secreted by most bladder cancers. This observation was exploited in the development of the BTA stat™ and BTA TRAK™ diagnostic assays, both of which make use of two factor H-specific monoclonal antibodies in sandwich format. Here we show that both antibodies exert interesting effects on the biochemistry of complement activation in in vitro systems. Antibody X13.2 competes with C3b for association with factor H and strongly inhibits factor H/factor I-mediated cleavage of C3b, thereby evidently inactivating a negative regulator of complement; yet, the antibody strongly inhibits complement-mediated lysis as well. Conversely, antibody X52.1, which does not compete with C3b and has no effect on solution-phase cleavage of C3b, is capable of enhancing complement-mediated lysis of various cell types, including cancer cells, by over 10-fold. Our observations indicate that it is possible to deconvolute the biochemical roles of factor H in complement by means of appropriate inhibitors, a finding with potentially valuable implications for both basic research and cancer therapy.

show abstract

Section: Summary Of Hemolysis Results and Control Proceduressupporting

confidence: 92%

“…Factor H, a soluble negative regulator of the complement system, is produced and secreted by most transitional cell carcinomas of the bladder (1)(2)(3). Complement factor H (FH) 1 is a 150-kDa protein whose structure and biological roles have been well described (Refs.…”

mentioning

confidence: 99%

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Corey¹,

Kinders²,

Poduje³

et al. 2000

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…The reported sensitivity rates of the BTA test for bladder cancer detection range widely between 28 and 82.8% [12, 13, 14, 15]. Contradictory to the report by Johnston et al [13]comparing BTA and FDP which concluded that the latter had better results, we previously had experience with the BTA test in 57 patients and found a specificity rate of 78% and an accuracy rate of 73%, both higher than the Accu–Dx rates [15].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Fibrin–Fibrinogen Degradation Products (Accu–Dx) Test in Bladder Cancer Patients

et al. 2001

View full text Add to dashboard Cite

“…In 220 patients with bladder cancer, Sarosdy et al [16]reported the sensitivities of BTA Stat Test and voided urine cytology as being 58 and 23%, respectively. BTA–Stat specificity decreased from 95% in primary diagnosis to 70% in patients with a positive history of bladder cancer.…”

Section: Discussionmentioning

confidence: 99%

Urinary BTA–Stat, BTA–Trak and NMP22 in Surveillance after TUR of Recurrent Superficial Transitional Cell Carcinoma of the Bladder

Serretta¹,

Pomara²,

Rizzo³

et al. 2000

European Urology

View full text Add to dashboard Cite

Improved detection of recurrent bladder cancer using the bard bta stat test

Cited by 178 publications

References 6 publications

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Assessment of Fibrin–Fibrinogen Degradation Products (Accu–Dx) Test in Bladder Cancer Patients

Urinary BTA–Stat, BTA–Trak and NMP22 in Surveillance after TUR of Recurrent Superficial Transitional Cell Carcinoma of the Bladder

Contact Info

Product

Resources

About

Improved detection of recurrent bladder cancer using the bard bta stat test

Cited by 178 publications

References 6 publications

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis

Assessment of Fibrin&ndash;Fibrinogen Degradation Products (Accu&ndash;Dx) Test in Bladder Cancer Patients

Urinary BTA&ndash;Stat, BTA&ndash;Trak and NMP22 in Surveillance after TUR of Recurrent Superficial Transitional Cell Carcinoma of the Bladder

Contact Info

Product

Resources

About

Assessment of Fibrin–Fibrinogen Degradation Products (Accu–Dx) Test in Bladder Cancer Patients

Urinary BTA–Stat, BTA–Trak and NMP22 in Surveillance after TUR of Recurrent Superficial Transitional Cell Carcinoma of the Bladder